Skip to main content
Clinical Trials/NCT03591081
NCT03591081
Completed
Not Applicable

A Feasibility Study to Explore the Implementation and Acceptance of INTELLIN, a Novel mHealth Application on the Management of People With Diabetes Who Have Recently Healed Foot Ulceration.

Natalie Garratt1 site in 1 country19 target enrollmentJune 22, 2018
ConditionsHealed Ulcer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Healed Ulcer
Sponsor
Natalie Garratt
Enrollment
19
Locations
1
Primary Endpoint
1 Acceptability, suitability and usability of the INTELLIN platform
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This is a novel feasibility study to test the participant acceptance and usability of a specifically designed smart phone app. It will also explore the effects of smart phone technology in improving self-referrals into the diabetic foot ulcer (DFU) service. Furthermore, it will be explored if this increase in self-referrals will influence the outcome of people with diabetes who have recently had a healed foot ulceration.

Detailed Description

The rationale behind this study is if the investigators can introduce a new technology (a smart phone app) which is acceptable to patients, engages them and prompts people to take preventative health behaviours then the investigators may be able to influence the low rates of appropriate self-referral. There is evidence that links poor glycaemic control and hypertension to DFUs, so engagement in these areas of wider diabetes management needs to be reviewed, the latest National Diabetes Audit (NDA) shows only 20% of people with Type 1 and 42% of people with Type 2 diabetes achieve the 3 NICE standards for HbA1c, BP and cholesterol. In addition, healthcare providers are being asked to investigate new systems that may increase patient engagement with and the uptake of the NICE 8 annual care processes. The latest NDA shows only 40% of patients with type 1 and 60% of patients with type 2 diabetes currently have all 8 .

Registry
clinicaltrials.gov
Start Date
June 22, 2018
End Date
March 20, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Natalie Garratt
Responsible Party
Sponsor Investigator
Principal Investigator

Natalie Garratt

Research & Development Lead

Northern Care Alliance NHS Foundation Trust

Eligibility Criteria

Inclusion Criteria

  • • 18 years of age will be screened to meet the eligibility criteria:
  • Consultant or GP diagnosis of diabetes mellitus (Type I or II) , documented on the electronic patient record with HbA1C greater than 48mmol/mol
  • History of a recent diabetes foot ulcer defined as being eligible for the national diabetes foot audit and classified as healed for at least 4 weeks and no more than 12 weeks
  • Able to provide informed consent
  • Has no reasons that they could not be part of the study for 12 months such as moving out the area for attending appointments or short life expectancy from a diagnosed illness
  • Owns a smart phone

Exclusion Criteria

  • No smart phone
  • Comorbidity such as poor eyesight which limits the use of smart phone
  • Participation in an interventional study within the last 30 days
  • Critical illness that prevents participating for a period of time

Outcomes

Primary Outcomes

1 Acceptability, suitability and usability of the INTELLIN platform

Time Frame: 12 months

A 5-point rating scale as assessed by the participants and the clinical team. The 5 point rating is a likert scale where respondants are offered a choice of 5 pre coded responses 1 being strongly disagree 2 disagree 3 (neutral point) niether disagree or agree 4 agree and 5 strongly agree so the individual can express how much they agree or disagree with the experience of using the application

The proportion of patients who self-refer for recurrence of diabetic foot-ulcer over a twelve-month period, compared with the current National diabetes foot audit average of 33.3%

Time Frame: 12 months

Proportion of participants self-referring using the Intellin platform SOS button over 12 months compared with the current National diabetes foot audit average of 33.3%

Secondary Outcomes

  • The proportion of patients with recurrence of foot ulcer over 12 months(12 months)
  • Proportion of patients who would recommend Intellin platform to others(12 months)
  • Proportion of patients who discontinue the study because they are unable to use the app(12 months)
  • Proportion of patients completing NICE 8 point annual checks over 12 months compared with the current national diabetes foot audit average of 60%(12 months)
  • Changes in cardiovascular markers(12 months)
  • Proportion of self-referrals that are deemed by the Clinician to be appropriate according to NICE guidelines(12 months)
  • Time to recurrence of ulcer over 12 months.(12 months)
  • The impact of using INTELLIN on healthcare utilisation and costs associated with Diabetic Foot Ulcers(12 months)
  • Proportion of patients who access the Intellin app every day(12 months)
  • The proportion of patients who report that the INTELLIN app has improved their understanding of the need for the 8 annual checks(12 months)
  • The proportion of patients who report that the INTELLIN app has improved their understanding of the management of their diabetes(12 months)
  • The effect of using INTELLIN on quality of life(12 months)
  • The proportion of patients with lower limb amputations(12 months)

Study Sites (1)

Loading locations...

Similar Trials